IN2012DN02196A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02196A IN2012DN02196A IN2196DEN2012A IN2012DN02196A IN 2012DN02196 A IN2012DN02196 A IN 2012DN02196A IN 2196DEN2012 A IN2196DEN2012 A IN 2196DEN2012A IN 2012DN02196 A IN2012DN02196 A IN 2012DN02196A
- Authority
- IN
- India
- Prior art keywords
- treatment
- relates
- autoimmune
- inflammatory disorders
- epratuzumab
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
The invention relates to the treatment of autoimmune or inflammatory disorders with antibodies to CD22. In particular, the invention relates to the treatment of autoimmune or inflammatory disorders with epratuzumab with a new dosing regimen. More particularly, the invention relates to the treatment of SLE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24379709P | 2009-09-18 | 2009-09-18 | |
PCT/EP2010/005225 WO2011032633A1 (en) | 2009-09-18 | 2010-08-26 | Treatment of autoimmune and inflammatory diseases with epratuzumab |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN02196A true IN2012DN02196A (en) | 2015-08-21 |
Family
ID=43063209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2196DEN2012 IN2012DN02196A (en) | 2009-09-18 | 2010-08-26 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20110070227A1 (en) |
EP (1) | EP2478012B1 (en) |
JP (1) | JP5816905B2 (en) |
KR (1) | KR20120100914A (en) |
CN (1) | CN102574920A (en) |
AU (1) | AU2010294905B2 (en) |
BR (1) | BR112012006035A2 (en) |
CA (1) | CA2774244A1 (en) |
EA (1) | EA026902B1 (en) |
ES (1) | ES2608661T3 (en) |
IN (1) | IN2012DN02196A (en) |
MX (1) | MX341117B (en) |
WO (1) | WO2011032633A1 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006138181A2 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
DK2789684T3 (en) | 2008-05-23 | 2017-02-20 | Siwa Corp | Methods and compositions for facilitating regeneration |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
CA3162352A1 (en) | 2010-10-01 | 2012-04-05 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
DE12722942T1 (en) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
PT3682905T (en) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9757458B2 (en) * | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
LT2791160T (en) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modified mrna compositions |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
CA2868996A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
RS56520B1 (en) | 2012-10-12 | 2018-02-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
PL2922554T3 (en) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Terminally modified rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
JP2016538829A (en) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | Polynucleotide encoding low density lipoprotein receptor |
EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
NZ726520A (en) | 2014-05-29 | 2018-12-21 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
EP3194439B1 (en) * | 2014-09-19 | 2022-01-19 | Siwa Corporation | Anti-age antibodies for treating inflammation and auto-immune disorders |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
CA3021150C (en) | 2016-02-19 | 2023-02-07 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
CN109311975A (en) | 2016-04-15 | 2019-02-05 | Siwa有限公司 | For treating the anti-AGE antibody of neurodegenerative disorder |
EP3475306A1 (en) | 2016-06-23 | 2019-05-01 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
WO2018075818A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
MX2019009428A (en) | 2017-02-08 | 2019-10-07 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates. |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
CA3059803A1 (en) | 2017-04-13 | 2018-10-18 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
HUE059828T2 (en) | 2017-04-18 | 2023-01-28 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
JP7408396B2 (en) | 2017-04-20 | 2024-01-05 | アーデーセー セラピューティクス ソシエテ アノニム | combination therapy |
BR112019026564A2 (en) | 2017-06-14 | 2020-06-30 | Adc Therapeutics Sa | dosing regimens for administration of an anti-cd19 adc |
LT3668874T (en) | 2017-08-18 | 2022-03-25 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
US20210380685A1 (en) * | 2018-10-18 | 2021-12-09 | Sinomab Bioscience Limited | Methods of Treating Rheumatoid Arthritis |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5484892A (en) * | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
IL114909A (en) * | 1994-08-12 | 1999-10-28 | Immunomedics Inc | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
DE60042785D1 (en) * | 1999-06-09 | 2009-10-01 | Immunomedics Inc | IMMUNOTHERAPY OF AUTOIMMUNE DISEASES THROUGH THE USE OF B-CELL SPECIFIC ANTIBODIES |
NZ581541A (en) * | 2002-10-17 | 2011-07-29 | Genmab As | Human monoclonal antibodies against CD20 |
EP1999148B8 (en) * | 2006-03-06 | 2014-03-05 | Medlmmune, LLC | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
SI2032606T1 (en) * | 2006-05-30 | 2014-02-28 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
US8283162B2 (en) * | 2009-03-10 | 2012-10-09 | Abbott Laboratories | Antibodies relating to PIVKAII and uses thereof |
-
2010
- 2010-08-25 US US12/868,338 patent/US20110070227A1/en not_active Abandoned
- 2010-08-26 WO PCT/EP2010/005225 patent/WO2011032633A1/en active Application Filing
- 2010-08-26 CN CN2010800412158A patent/CN102574920A/en active Pending
- 2010-08-26 ES ES10751563.7T patent/ES2608661T3/en active Active
- 2010-08-26 EP EP10751563.7A patent/EP2478012B1/en active Active
- 2010-08-26 CA CA2774244A patent/CA2774244A1/en not_active Abandoned
- 2010-08-26 AU AU2010294905A patent/AU2010294905B2/en not_active Ceased
- 2010-08-26 IN IN2196DEN2012 patent/IN2012DN02196A/en unknown
- 2010-08-26 EA EA201270433A patent/EA026902B1/en not_active IP Right Cessation
- 2010-08-26 KR KR1020127009393A patent/KR20120100914A/en not_active Application Discontinuation
- 2010-08-26 BR BR112012006035A patent/BR112012006035A2/en not_active IP Right Cessation
- 2010-08-26 JP JP2012529137A patent/JP5816905B2/en not_active Expired - Fee Related
- 2010-08-26 MX MX2012002907A patent/MX341117B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO2011032633A1 (en) | 2011-03-24 |
EP2478012B1 (en) | 2016-11-09 |
EA201270433A1 (en) | 2012-10-30 |
US20110070227A1 (en) | 2011-03-24 |
ES2608661T3 (en) | 2017-04-12 |
MX341117B (en) | 2016-08-09 |
JP5816905B2 (en) | 2015-11-18 |
CA2774244A1 (en) | 2011-03-24 |
AU2010294905A1 (en) | 2012-04-05 |
BR112012006035A2 (en) | 2019-09-24 |
MX2012002907A (en) | 2012-04-30 |
EP2478012A1 (en) | 2012-07-25 |
JP2013505205A (en) | 2013-02-14 |
AU2010294905B2 (en) | 2016-09-22 |
EA026902B1 (en) | 2017-05-31 |
CN102574920A (en) | 2012-07-11 |
KR20120100914A (en) | 2012-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02196A (en) | ||
MX2011011925A (en) | Tri- or tetraspecific antibodies. | |
IL227081B (en) | Modified antibody with improved half-life | |
AU333675S (en) | Bottle | |
AU333674S (en) | Bottle | |
AP2012006190A0 (en) | Herbicide-tolerant plants. | |
CA143394S (en) | Microwavable bag | |
AP2012006163A0 (en) | Boron-containing small molecules as antiprotozoal agents. | |
WO2012081924A3 (en) | Bicycle | |
MX350335B (en) | Antibodies that bind integrin alpha-v beta-8. | |
CA138917S (en) | Beverage package | |
MX349282B (en) | Cross-linked organosilicon polysulfides. | |
PL2602805T3 (en) | Gehäuse für Schutzvorrichtung gegen Überlastspannungen, und entsprechende Schutzvorrichtung gegen Überlastspannungen | |
WO2010007168A3 (en) | Treatment of rheumatoid arthritis with mammal beta defensins | |
WO2010136104A3 (en) | Anti-dandruff agents | |
MX2012010317A (en) | β-hydroxyalkylamides, method for their production and use thereof. | |
TWI561442B (en) | Strap with improved column stiffness | |
GB201107632D0 (en) | Elastic mount, in particular rubber-metal mount | |
MX2012012509A (en) | Tapentadol for use in the treatment of irritable bowel syndrome. | |
CA141110S (en) | Bottle | |
AP2012006243A0 (en) | Saddle type vehicle. | |
FR2948310B1 (en) | ESTABLISHED OF THE KIND TABLE, REPLIABLE | |
AP2010000342S (en) | Tusker bottle. | |
GB201113152D0 (en) | The express add | |
PL118767U1 (en) | Elastic insert, preferably for the mining support sill piece |